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Introduction
Juvenile idiopathic arthritis (JIA) is the most common
arthritis disease of childhood and is an important cause
of disability. Methotrexate (MTX) is the mainstay treat-
ment in JIA. Unfortunately, 30-35% of patients fail to
respond MTX, and the delay in identifying the optimal
treatment at an early stage of disease can lead to long-
term joint damage. Recent studies have evaluated com-
prehensively the effect of genetic variants in candidate
genes involved in MTX pharmacokinetics and pharma-
codynamics on the response to the medication in chil-
dren with JIA. These studies seem to indicate that the
most relevant variants to predict MTX response in JIA
are those in ATIC, ITPA and SLC19A1 genes.
Objectives
To evaluate the role of these candidate genetic factors
on the attainment of clinical remission on MTX in an
Italian cohort of children with JIA.
Methods
Patients with JIA treated with MTX were enrolled by
the Pediatric Clinic of Burlo Garofolo Children’s Hospi-
tal in Trieste; clinical data was collected retrospectively
from patients’ charts. Clinical remission on MTX for 6-
month-period was evaluated according to Wallace cri-
teria. The most relevant functional SNP for each gene
considered was characterized by Taqman (rs2372536 in
ATIC, rs1127354 in ITPA) or PCR-RFLP (rs1051266 in
SLC19A1) assays on patients’ DNA extracted from per-
ipheral blood.
Results
Complete analysis was performed on 69 patients. Of
these, 76.8% were female, median age at MTX start was
8 years (range 1 - 22). JIA presentation was oligoarticular
in 63.7%, poliarticular in 33.3% and enthesitic/psoriatic in
2%. At the beginning of MTX therapy, disease had been
lasting for a median of 1 year (range 0 - 19); MTX was
administered at a median dose of 15 mg/m2 (range 10 -
20), subcutaneously in 62.3% of patients and orally in the
rest. Genotyping showed minor allele frequencies of
36.2% for rs2372536, 5.1% for rs1127354 and 49.3% for
rs1051266, consistent with previous reports in Europeans.
Assessment of response to MTX showed that 27.5% of
reached remission stable for 6 months. No statistically
significant effect of the demographic and clinical covari-
ates was found on MTX response. However, genotyping
analysis identified a significant association between the
GG variant of ATIC rs2372536 and improved response
to therapy: frequency of this genotype was 32% among
patients with stable remission and 6% among those with
no stable remission (p = 0.010). For the variant of ITPA
rs1127354, an effect was present in the opposite direc-
tion: the A allele was present present in none of the
patients with stable remission and in 12% of those with-
out stable remission (p = 0.04). Preliminary analysis of
SLC19A1 rs1051266 revealed a trend for an association
of the variant with increased response (p = 0.06). Multi-
variate analysis supports the independent effect of the
genotypes considered on methotrexate response.
Conclusion
This report supports the utility of genotyping candidate
genes to predict MTX response in children with JIA and
should be further validated clinically by larger and pro-
spective studies.
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